Home » Newsletters » BioWorld Science

BioWorld Science

March 1, 2016

View Archived Issues

Baxalta and Precision BioSciences enter into global immune-oncology collaboration

JDRF and Sanofi expand diabetes research collaboration

AstraZeneca and CMS sign agreements regarding Plendil and Imdur

Phase I study to evaluate oral DpC in patients with advanced solid tumors

FDA clears IND for phase I/II clinical study evaluating ABO-102 gene therapy for MPS IIIA

Aldeyra Therapeutics reports positive phase IIa results for NS-2 in allergic conjunctivitis

Phase IIb tremelimumab monotherapy trial in mesothelioma misses primary endpoint

GeoVax and USAMRIID to collaborate on development of tetravalent hemorrhagic fever vaccine

Thrasos announces successful outcome to phase II trial of THR-184 to prevent acute kidney injury

Immune-suppressing drug improves cognition in patients with schizophrenia

Alexza Pharmaceuticals and Ferrer enter into a non-binding letter of intent

EMA committee recommends approval of Giotrif for advanced squamous cell carcinoma of the lung

Ortho-McNeil-Janssen Pharmaceuticals patents GluN2B receptor antagonists

CSPC Zhongqi Pharmaceutical Technology discloses anticancer agents

Chinese scientists describe H+/K+-ATPase inhibitors

Shionogi and Roche sign license and collaboration agreement for anti-influenza drug

Hydra Biosciences reports TRPC5 antagonists

Intra-Cellular Therapies presents PDE1A and/or PDE1C inhibitors

University of Queensland and Pfizer partner on drug discovery

Sellas' WT1 cancer vaccine awarded U.S. orphan drug designation for malignant pleural mesothelioma

Provectus initiates phase I study of PV-10 in neuroendocrine tumors metastatic to the liver

Results from NIH-funded trial comparing Eylea, Avastin and Lucentis in diabetic macular edema

Applicator-free vaginal estradiol softgel capsule shows efficacy and safety for symptomatic VVA

Immunovia establishes collaboration to evaluate IMMray diagnostics test for SLE

Concert's CTP-656 has superior pharmacokinetic profile to Kalydeco in ongoing phase I study

Exelixis and Ipsen sign licensing agreement for cabozantinib outside U.S., Canada and Japan

CYFRA 21-1 shows promise as a prognostic marker of tumor response in LXC and HPC SCC